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Abstract
Background: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in 
patients suffering from chronic heart failure (CHF). Optimal device programming is crucial 
for maximum patient benefit. The goal of the present study was to assess device settings from 
CHF patients undergoing CRT optimization in a “real world” setting, and to delineate 
parameters most frequently requiring adjustment.
Methods: All patients who underwent CRT device implantation in the Cardiology Clinic at 
the University Hospital Zurich between January 2011 and September 2012 and in whom 
follow-up was available were included in this analysis. 
Results: A total of 170 CHF patients were included in this analysis. True biventricular pacing 
was present in 44.0% of all patients, while QRS fusion was detected in 49.9%. The majority 
of the patients presented with suboptimal AV delays requiring adjustment. AV delays were 
therefore shortened due to the presence of QRS fusion in 53.3% and 38.1% of patients (sAV 
and pAV, respectively) or prolonged because of truncation of the A wave in the LV inflow 
pulse wave Doppler measurement (17.5% and 28.4% for sAV and pAV, respectively). In 
contrast, interventricular delay (VV delay) was rarely changed (11.9%).
Conclusions: In our “real world” cohort, a substantial proportion of patients presented to their 
first post-operative consultation with suboptimal device settings. Our data indicate that the 
opportunity to optimize device settings is frequently wasted in the “real world”, underlining 
the necessity for expert device follow-up to deliver optimal care to this challenging group of 
heart failure patients.
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Introduction
Cardiac resynchronization therapy (CRT) has become a cornerstone in the treatment of 
chronic heart failure (CHF)1, 2. Indeed, several clinical trials observed a reduction in morbidity 
and mortality as compared to medical therapy alone in patients suffering from symptomatic 
left ventricular (LV) dysfunction (LV ejection fraction ≤35%) with a prolonged QRS duration 
(≥120 ms). Nevertheless, almost 30% of patients do not exhibit an improvement in clinical 
symptoms or hemodynamic parameters after CRT implantation (so-called “non-responders”)3. 
This lack of improvement may be due to pre-implantation characteristics such as large areas 
of scar tissue due to coronary artery disease or a lack of mechanical dyssynchrony4. 
Suboptimal LV lead position further represents a reason for a lack of benefit4. Additionally, 
however, some patients do not respond to CRT due to suboptimal CRT device settings, 
impairing LV filling (atrioventricular (AV) dyssynchrony) and / or persistent LV 
dyssynchrony5. 
At the University Hospital of Zurich, we implemented a standard protocol by which 
every patient with a CRT device undergoes complete device optimization 3-6 months after 
implantation and again on a yearly basis or if clinically deemed necessary. The goal of the 
present study was to summarize clinical presentation, echocardiographic findings, and device 
settings from chronic heart failure (CHF) patients undergoing CRT optimization in this “real 
world” setting, unraveling the amount of patients presenting with suboptimal settings, as well 
as the parameters most frequently requiring adjustment. We provide a rational for the 
necessity of implementing a routine protocol for the integrated management of these complex 
CHF patients, including expert device management. 
Methods
Study population and CRT implantation
All patients with a CRT device receiving their first device follow-up in our specialized 
device clinic from January 1st 2011 until September 2012 were prospectively included. The 
study was approved by the cantonal ethics committee Zurich. Mean time from implantation to 
optimization was 2.9 months (Tab. 1). Indications for CRT implantation were based on 
current guidelines1. CRT devices were implanted by a standard procedure under local 
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anesthesia. Devices and leads from Biotronik, Boston Scientific / Guidant, Medtronic and St. 
Jude Medical were used. For implantation of the left ventricular (LV) lead, percutaneous 
placement into a lateral or postero-lateral vein was attempted whenever possible. If no 
suitable vein branch was available epicardial lead implantation was performed. 
Follow up protocol
We implemented a standard protocol by which every patient with a CRT device 
undergoes a comprehensive and standardized device follow-up and optimization procedure. 
After a complete clinical assessment by a heart failure specialist, a comprehensive device 
follow-up was performed by implantable electronic cardiac device specialists (JS/DH), 
including complete check of the system with 12-lead ECG, and review of all brady- and 
tachycardia parameters. Subsequently, a complete echocardiographic exam was performed 
(Vivid E9, GE), followed by optimization of the AV- and VV delay if necessary. AV delay 
optimization was performed starting at a long AV-delay without intrinsic conduction. The 
AV-delay was then progressively shortened in steps of 20ms until truncation of the A-wave 
was observed. Then, the AV-delay was prolonged in 10ms steps until the optimal separation 
of E/A wave without truncation of the A-wave is reached, which was considered the optimal 
AV-delay. 
Results
Study population 
A total of 170 chronic heart failure patients were included in this prospective analysis. 
Baseline demographic data at implantation as well as clinical characteristics at time of follow-
up are summarized in table 1. The majority of patients were men (76.5%), and had a 
cardiovascular risk profile typical of a real-world chronic heart failure cohort as previously 
shown6. All patients were on optimal medical therapy including ACE-inhibitors or 
angiotensin-II-blockers (95.2%), beta-blockers (93.5%) and diuretics (86.3%) prior to 
implantation. Furthermore, more than fifty percent of patients were treated with an 
aldosterone antagonist (55.4%) in addition to standard diuretic therapy, and received anti-
arrhythmic treatment with either digitalis (13.1%) or amiodarone (17.9%). 
Echocardiographic and electrocardiographic parameters at follow-up
Most patients demonstrated a reduced LVEF (mean 37.3±11.1%) and a dilated left 
ventricle (enddiastolic volume index 88.4±41.6ml/m2; Tab. 2). Of note, parameters of 
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dyssynchrony at this time mainly demonstrated values within our lab’s predefined normal 
values (IVMD <40 ms, TDIseptal-lateral <60 ms, TDIanteroseptal-posterolateral <60), with an interventricular 
mechanical delay (IVMD) of 17.5±27.7 as well as 32.7±46.8ms and 33.5±46.3ms for septal-
lateral and anteroseptal-posterolateral delay assessed by tissue Doppler imaging (TDI), 
respectively. The mean intrinsic QRS duration was 150±26.6ms with an ECG pattern of 
LBBB in the majority of cases (59.5%), and an average PQ interval of 184.7±27.6ms (Table 3
). At time of implantation and at first follow-up, most patients were in sinus rhythm (65.9%). 
While 65.3% of the patients had the same rhythm at our follow-up visit, a minority of patients 
switched from atrial fibrillation to sinus rhythm (2.4%) and vice versa (4.8%). 
Device settings and intervals at time of optimization
True biventricular pacing was present in nearly half of the patients at the time of 
optimization (44.7%), while QRS fusion could be detected in 39.4% of cases (Table 4, Fig. 1
). At time of optimization, average sensed AV (sAV) delay was 110.5± 19ms and paced AV 
(pAV) 136.5±23.4ms. QRS fusion as diagnosed by 12-lead surface ECG began to appear at 
an average sAV of 103.9±37.1ms and an average pAV of 136.5±23.4ms, respectively. 
A biventricular pacing rate of more than 95% was present in 85.8% of patients from 
the studied cohort. Main reason for a low biventricular pacing percentage was either atrial 
fibrillation or frequent ventricular extrasystolies. At time of follow-up, mean programmed 
interventricular (VV) delay was 8.5±14.4ms (LV first). 
Left ventricular lead settings
In a third of all cases, lead pacing configuration was “true” bipolar from the LV lead 
tip (LvTip) to the LV ring (LvRing; 34.1%) or between LvTip to the right ventricular lead 
ring (RvRing; 28.2%, Table 5). In every fifth patient, the pacing vector was between the 
LvTip and the coil of the RV lead (RvCoil; 23.5%). With these configurations, only a 
minority of patients (n=7, 4.2%) were suffering from diaphragmatic capture (4.2%). The latter 
was solved in all cases by reprogramming.
Optimization of CRT settings after implantation
In the majority of all patients who underwent CRT device implantation, the 
programmed AV intervals were deemed suboptimal during follow-up and were subsequently 
reprogrammed (Table 6). AV delays were shortened (sAV delay in 53.3%, pAV delay in 
38.1% of the patients) mainly due to the presence of QRS fusion on the 12-lead ECG. In 
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contrast, the AV delay was prolonged in only 17.5% and 28.4% (sAV and pAV, respectively), 
mostly due to truncation of the A wave in the LV inflow pulse wave Doppler measurement. In 
77 patients (45% of the entire cohort), some degree of QRS fusion was accepted in order to 
allow for better LV filling.
In contrast to the adjustments of the AV interval, the VV delay was left unchanged in 
the majority of patients (88.1%). The main reason for a change in VV delay was 
intraventricular dyssynchrony observed on TDI (82.4%).
Thirty three (19.4%) of patients in or cohort suffered from atrial fibrillation. By virtue 
of this, AV optimization was impossible in these patients and VV optimization greatly 
impaired. Of our patients with AF, 20 (61%) had intrinsic conduction, whereas 7 (21.2%) and 
6 patients (18.2%) had no intrinsic AV conduction or underwent AV node ablation, 
respectively (Tab. 3). 
Discussion
The aim of the present study was to give an overview on CRT settings at the time of 
device implantation and to demonstrate the potential for optimization by comprehensive 
assessment during follow-up in an integrative device clinic. In view of the substantial 
discrepancy between programmed parameters and optimal values, our data indicate that this 
opportunity is frequently missed in the “real world”, providing a rational for the necessity of 
protocol-oriented expert follow-up and optimization procedures for these patients.  
AV delay optimization and QRS fusion
Whether and how AV intervals should regularly be evaluated and adjusted remains a 
matter of debate8, 9. In various preliminary studies, optimization of the AV delay has been 
demonstrated to significantly increase hemodynamic response, NYHA class, LV ejection 
fraction and brain natriuretic peptide level in the short-time follow-up10-14. In contrast, the 
recently published ‘SmartDelay determined AV Optimization: A comparison to Other AV 
Delay Methods Used in Cardiac Resynchronization Therapy’ (SMART-AV) trial implied 
otherwise. In this study, CRT device recipients were randomized to a fixed empirical AV 
delay of 120ms, an echocardiographically optimized AV delay or a device-based AV 
optimization algorithm (SmartDelay)15. The primary endpoint, left ventricular end-systolic 
volume at 6 months after implantation did not differ between the 3 groups. As discussed by 
the authors, it may be possible that the observed acute beneficial hemodynamic effects after 
CRT implantation are not sufficient enough to result in an improvement of hard clinical 
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endpoints. On the other hand, the follow-up period of only 6 months may have been too short 
to evaluate such endpoints. 
Furthermore, it has to be kept in mind that the optimal AV delay may have a high 
variability among CRT patients5, 16. As such, data from SMART-AV do not imply that 
individual patients with suboptimal AV delay may not profit from an optimization procedure. 
Indeed, this has been substantiated most recently in a subanalysis from MADIT-CRT, in 
which patients with short AV-delays (notably < 120ms) had a superior outcome compared to 
those with longer AV delays.17 Our data demonstrate that programming an empirical setting of 
120ms for the sensed AV delay was suboptimal in terms of true biventricular stimulation in 
the vast majority of patients (57.1%), and 8 patients (5.7%) even demonstrated entirely 
intrinsic conduction or pseudofusion (and hence loss of biventricular pacing) at this setting. 
Furthermore, a subanalysis of the Clinical Evaluation on Advanced Resynchronization 
(CLEAR) pilot study revealed that systematic CRT optimization was associated with a higher 
percentage of improved patients based on the composite endpoint (all-cause mortality, heart 
failure-related hospitalization, NYHA functional class, and Quality of Life score), fewer 
deaths and fewer hospitalizations.18 These data clearly indicate a role for CRT optimization 
over standard programming in all patients.
Moreover, the mean interatrial delay was markedly longer (71.9±28.2ms, Table 4) 
than the standard programmed difference between sensed and paced AVD (usually 30-40ms) 
found in the default settings, further supporting an individualized approach to AVD 
programming.
The majority of our patients (>70%) underwent reprogramming of the AV delay. One 
of the most important parameters to guide AV delay optimization is the level of true 
biventricular pacing or, vice versa, the degree of QRS fusion as a result of intrinsically 
conducted ventricular excitation19-21. In our cohort, 45.3% of patients presented with an AV 
delay too long to avoid any QRS fusion. However, whether some degree of ventricular fusion 
may be clinically beneficial remains a matter of debate, as a certain amount of QRS fusion has 
been shown to improve hemodynamics22, 23,24. Fusion allows for intrinsic excitation of the RV 
via the normal-conducting right bundle branch which may result in improved RV 
contraction25. A recent study further demonstrated that the maximal rate of LV pressure 
increase (dP/dt) was higher in LV pacing combined with intrinsic conduction as compared to 
biventricular pacing22. Based on these data, we accepted some degree of QRS fusion in order 
to allow for optimal LV filling in those cases where it was impossible to shorten the AV delay 
to the point of complete loss of QRS fusion (Fig. 1). Importantly, intrinsic conduction and 
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pseudofusion could entirely and sustainably be avoided in all patients presenting with these 
findings.
VV delay optimization
For various reasons, VV delay optimization appears to be less important as compared 
to AV delay optimization. Even though an improvement in hemodynamic conditions has been 
observed after optimization of VV intervals26-28, other randomized trials failed to find a 
beneficial effect29, 30. The latter may, at least in part, be due to the fact that VV delay 
optimization was performed in the majority of patients on top of AV delay optimization. In a 
small study investigating the effect of simultaneous AV and VV time optimization, an 
additional but smaller beneficial effect of VV delay optimization was found31. in our cohort, 
only a minority of patients underwent VV optimization, mainly due to the fact that it was not 
deemed necessary due to satisfying echocardiographic dyssynchrony parameters and, 
coherently, visual impression of synchronous LV contraction. In patients who were 
optimized, the indication was mainly driven by TDI values during echocardiographic 
evaluation. Conversely, 30 patients (17.9%) were dyssynchronous either visually or by TDI 
measurements, but could not be corrected by advancing LV or RV activation. As a result, and 
due to the lack of clear evidence for a benefit, VV optimization is only performed in special 
cases in our institution.
CRT in patients with AF
19.4% of patients in or cohort suffered from atrial fibrillation. These patients pose a 
challenge in CRT as the uncoordinated and often rapid intrinsic conduction often results in a 
substantially impaired rate of biventricular pacing (<95%). Indeed, AF was the main reason 
for a low percentage of biventricular pacing in our cohort. Pharmacologically, amiodarone has 
been shown to be most effective and safe for rhythm control in atrial fibrillation patients with 
heart failure32, and, as a consequence, is frequently used to increase the percentage of 
biventricular stimulation. If medical therapy is insufficient, AV nodal ablation is 
recommended as the next step33. In our cohort, 39.4 % of patients with AF ultimately had no 
intrinsic AV conduction and, consequently, had a high degree of biventricular pacing. 
Limitations
Our study has some inherent limitations. Data are only collected from a single tertiary 
care center, and may hence not be generalizable to other healthcare settings. We do, however, 
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believe that most interpretations and statements characteristically reflect the situation of “real 
world” CRT patients, and are therefore important for therapy optimization of these 
individuals. The study is further limited by the fact that we focused on the necessity and 
possibilities for CRT optimization, and as such did not assess clinical or echocardiographic 
outcome in these patients, which was beyond the scope of this study. However, evidence is 
accumulating as indicated above that empirical AV delay programming cannot generally be 
recommended.17 As such, our data do indicate that specialist follow-up of CRT recipients is of 
crucial importance in order to provide optimal care for these complex patients, which was the 
primary aim of the current study. 
Conclusions and perspective 
In our “real world” cohort, a substantial proportion of patients presented with 
suboptimal device settings. Data from previous studies demonstrate that device optimization 
is associated with improved outcome.17, 18 Yet, our data indicate that this opportunity is 
frequently missed in the “real world”, underlining the necessity for expert follow-up to deliver 
optimal care to this challenging group of heart failure patients in order for them to benefit 
most of their devices.
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Table 1:   Demographics at implantation 
Men (years) 130/170 (76.5%)
New implantation 129/170 (75.9%)
CRT Upgrade 41/170 (24.1%)
Time implantation – optimization 
(months) 2.9 +/- 5
Age at implantation (years) 62.8 +/- 12.5
Ischemic cardiomyopathy 75/169 (44.4%)
CRT-D 156/170 (91.8%)
Sinus rhythm at implantation 107/167 (64.1%)
Table 2:   Clinical parameters at time of optimization 
Clinical
Height (m) 1.7 +/- 0.1
Weight (kg) 82 +/- 18.5
BMI (kg/m2) 28.4 +/- 5.9
Systolic BP (mmHg) 116.1 +/- 17.3
Diastolic BP (mmHg) 73 +/- 11.7
NYHA class
   NYHA I 24/134 (17.9%)
   NYHA II 54/134 (40.3%)
   NYHA III 20/134 (14.9%)
   NYHA IV 1/134 (0.7%)
 
Medication
Beta blocker 157/168 (93.5%)
ACE-I / ARB 160/168 (95.2%)
Spironolactone 93/168 (55.4%)
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Other diuretics 145/168 (86.3%)
Digitalis 22/168 (13.1%)
Amiodarone 30/168 (17.9%)
Calcium channel blocker 11/168 (6.5%)
Nitrates 11/168 (6.5%)
Lipid lowering treatment 103/168 (61.3%)
Aspirin 84/168 (50%)
Clopidogrel 12/168 (7.1%)
Oral anticoagulation 84/168 (50%)
Table 2:   Echocardiography at optimization 
 
LVEF (%) 37.3 +/- 11.1
LVEDD (mm) 6.2 +/- 1.1
LVESD (mm) 4.9 +/- 1.3
Enddiastolic volume (ml) 169.5 +/- 79.2
Enddiastolic volume index (ml/m2) 88.4 +/- 41.6
Endsystolic volume (ml) 110.8 +/- 71.5
Endsystolic volume index (ml/m2) 58.8 +/- 38.3
Diastolic dysfunction
   No diastolic dysfunction 92/168 (54.8%)
   Grade I 7/168 (4.2%)
   Grade II 1/168 (0.6%)
   Grade III 0/168 (0%)
Mitral regurgitation
   Minimal 88/167 (52.7%)
   Mild 59/167 (35.3%)
   Moderate 13/167 (7.8%)
   Severe 4/167 (2.4%)
LA-ESD (mm) 4.7 +/- 0.9
RV: Area D (cm2) 16.2 +/- 5.1
Fractional shortening RV (%) 39.7 +/- 12.1
TAM (mm) 18.3 +/- 4.9
RV/RA-pressure gradient (mmHg) 27.9 +/- 11.6
RA Size 5 +/- 0.9
Dyssynchrony assessment
   RV-PEP (ms) 118.1 +/- 31.3
   LV-PEP (ms) 135.5 +/- 31.5
   IVMD 17.5 +/- 27.7
   TDI SL 32.7 +/- 46.8
   TDI AS-IL 33.5 +/- 46.3
   Diastolic filling time / RR-
interval 49.5 +/- 32.1
Table 3:   ECG parameters 
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Rhythm at optimization
   Sinus rhythm 112/170 (65.9%)
   SR, AVB III°, without ventricular 
escape
15/170 (8.8%)
   SR, AVB III°, with ventricular 
escape
6/170 (3.5%)
   Atrial fibrillation with AV 
conduction
20/170 (11.8%)
   AF, AVB III° 7/170 (4.1%)
   AF post AVN ablation 6/170 (3.5%)
PQ intrinsic 184.7 +/- 27.6
QRS intrinsic 150 +/- 26.6
Bundle branch block
   No block 14/163 (8.6%)
   LBBB 97/163 (59.5%)
   RBBB 13/163 (8%)
   AVB III° 36/163 (22.1%)
 
Development of rhythm
   Unchanged 109 (65.3%)
   AF --> SR 4 (2.4%)
   AF --> PM 2 (1.2%)
   SR --> AF 8 (4.8%)
   SR --> PM 4 (2.4%)
   PM Upgrade 41 (24%)
Table 4:   AV / VV settings at optimization 
Pacing at optimization
   True biventricular stimulation 76/170 (44.7%)
   Fusion 67/170 (39.4%)
   Pseudofusion 3/170 (1.8%)
   Atrial fibrillation 23/170 (13.5%)
 
AV delays
   sAV (at interrogation) 110.5 +/- 19
   pAV (at interrogation) 136.5 +/- 23.4
   Begin QRS fusion (sAV) 103.9 +/- 37.1
   Begin QRS fusion (pAV) 174.3 +/- 42.7
   Intraatrial delay (pAV-sAV) 71.9 +/- 28.2
No fusion (AV block) 33 (19.4%)
Dynamic AV delay on 78/164 (47.6%)
Situation at sensed AV delay 120ms
   Pure biventricular stimulation 58/140 (41.4%)
   Fusion 72/140 (51.4%)
   Intrinsic rhythm / Pseudofusion 8/140 (5.7%)
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Status before optimization
   A-wave truncation 38/147 (25.9%)
   QRS fusion 39/147 (26.5%)
   Both A-wave truncation and QRS fusion 31/147 (21.1%)
 
VV (at interrogation) in ms 8.5 +/- 14.4
 
% Biventricular pacing (average) 94.3 +/- 13.3
≥ 97% 112 (67.9%)
< 97% 53 (32.1%)
< 95% 40 (24.2%)
< 90% 23 (13.9%)
≤ 85% 16 (9.7%)
 
Reason for low biventricular pacing (<95%)
   Atrial fibrillation 18/39 (46.2%)
   VES 13/39 (33.3%)
   Intrinsic conduction 3/39 (7.7%)
   Other 4/39 (10.3%)
 
Device manufacturer
   Medtronic 31/170 (18.2%)
   St. Jude Medical 49/170 (28.8%)
   Biotronik 79/170 (46.5%)
   Boston Scientific 10/170 (5.9%)
Table 5:   LV lead parameters 
LV pacing configuration
   LvTip-LvRing 58/170 (34.1%)
   LvRing-LvTip (inverse bipolar) 5/170 (2.9%)
   LvTip-RvRing 48/170 (28.2%)
   LvRing-RvRing 9/170 (5.3%)
   LvTip-RvCoil 40/170 (23.5%)
   LvRing-RvCoil 7/170 (4.1%)
   Unipolar 1/170 (0.6%)
 
Diaphragmatic capture
   No diaphragmatic capture 161/168 (95.8%)
   Diaphragmatic capture, resolved with programming 7/168 (4.2%)
   Diaphragmatic capture, not amenable to programming 
changes 0/168 (0%)
 
Threshold LV (V) 1.3 +/- 0.8
Threshold LV (ms) 0.5 +/- 0.2
LV Sensing mV 12.6 +/- 8.6
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LV Impedance 644.4 +/- 228.3
Table 6:   Changes during optimization 
Change in sensed AV delay
   unchanged 39/137 (28.5%)
   shortened 73/137 (53.3%)
   lengthened 24/137 (17.5%)
 
Changes in paced AV delay
   unchanged 45/134 (33.6%)
   shortened 51/134 (38.1%)
   lengthened 38/134 (28.4%)
 
Reason for AV delay change
   ECG Fusion 56/97 (57.7%)
   LV inflow truncation 23/97 (23.7%)
   LV inflow fusion 14/97 (14.4%)
   Visual LV filling 3/97 (3.1%)
   Other 1/97 (1%)
 
Status after optimization
   A-wave truncation 22/147 (15%)
   QRS fusion 47/147 (32%)
   Both A-wave truncation and QRS 
fusion
34/147 (23.1%)
 
Change in VV delay
   unchanged 118/168 (70.2%)
   LV earlier 13/168 (7.7%)
   RV earlier 5/168 (3%)
   Dyssynchronous, not improvable 30/168 (17.9%)
 
Reason for VV delay changes
   Visual 3/17 (17.6%)
   TDI 14/17 (82.4%)
Figure 1. Twelve-lead ECGs of a patient presenting for CRT optimization. “True” 
biventricular pacing (VVI 90 beats per minute, left panel), intrinsic rhythm (right panel) and 
rhythm at follow-up (middle panel) are shown. Note the significant degree of QRS fusion as 
demonstrated by 12-lead ECG with the current device settings. The latter are best appreciated 
in I, avL and V3, indicating the necessity for comprehensive 12-lead ECG analysis in the 
follow-up of these patients.
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Figure 2. CRT patient follow-up algorithm as implemented at the University of Zurich. See 
text for details
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Complete Device Check
12-lead ECG, including:
- Intrinsic rhythm
- Right ventricular pacing
- Left ventricular pacing
AV Delay optimization (12 lead ECG)
- Assess “True biventricular“ paced  rhythm
- Start at lowest possible AVD
- incremental increase of AVD until signs of fusion on ECG
- Repeat for sensed and paced AVD
Echocardiography
- Standard examination (if required)
- AVD optimization
- Assessment of VV dyssynchrony (TDI)
- VVD optimization, if required
Reassess AVD 
for ECG fusion 
if VVD has 
been adjusted
Wrap up
- Print 12-lead ECG with current setting
- Print current device settings
- Comprehensive report, including rationale for 
setting changes
- Review with heart failure specialists and discuss 
pertinent findings
